The Europe real time polymerase chain reaction market size is expected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising frequency of Infectious diseases, tumors, cardiometabolic conditions, and increasing ageing population in the region. The outbreak of the COVID-19 pandemic has brought a dynamic growth of the market due to the wide adoption of the test to detect the virus.
Real time polymerase chain reaction (RT-PCR) is a critical molecular diagnostic technique primarily used in clinical laboratories for early detection of infectious and viral diseases. The RT-PCR testing devices are considered to be useful in diagnosing the presence of infectious diseases as these devices produce reliable, precise, and multiple outcomes in a single run.
There are two typical approaches for detecting PCR results. The first one is non-specific fluorescent dyes that intercalate with any double-stranded DNA and second one is sequence-specific DNA probes made up of oligonucleotides labelled with a fluorescent reporter that allows detection only after hybridization of the probe with its corresponding sequence.
As the pandemic continued to affect millions of lives across the globe, several governments have encouraged the establishment of several healthcare units and clinical laboratories to increase RT-PCR testing. The testing can effectively detect the presence of the virus in a body and once an individual is tested COVID-19 positive, he/she would be advised to stay isolation or follow quarantine process to curb the spread of the virus. With constantly rising cases of the COVID-19 due to harsh effects from the second wave of the pandemic, it is mandatory for all passengers traveling in the commercial airlines have to undergo RT-PCR test.
Market Trends, Drivers, Restraints, and Opportunities
- Surge in COVID-19 cases in Europe and strict implementation of policies to curb the virus spread using the RT-PCR test are expected to boost the market growth.
- Development of technologically advanced instruments with high precision, portability, and cost-effectiveness is expected to propel the market growth during the forecast period.
- Availability of user-friendly features, a stable machine framework, and outstanding support capabilities are key factors driving the market expansion.
- Growing application in clinical diagnostics, rising need for customized and precision medicine, technical improvements, and applications in drug discovery are projected to propel the market expansion in the coming years.
- Rising demand for the clinical diagnostics and strict regulation for mandatory use of the test from government bodies and authorities to curb the COVID-19 spread are acting as key factors for fueling the market.
- Increasing awareness of personalized medicine, which seeks to give some targeted therapy to individual patients based on the molecular basis of disease, has boosted the market expansion.
Scope of Real Time Polymerase Chain Reaction Market Report
The report on the Europe real time polymerase chain reaction market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Europe Real Time Polymerase Chain Reaction Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Instruments (Applied Biosystems/Life Technologies [7500, QuantStudio Dx Reagents, ViiA 7 Dx, and StepOne/ StepOne Plus], Roche [LightCycler 2.0, Cobas 4800, and LightCycler 480], Bio-Rad [CFX96], Cepheid [SmartCycler], Qiagen [Rotor-Gene Q], and Eppendorf [MasterCycler])
|
Regional Scope
|
Europe
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Applied Biosystems/Thermo Fischer Scientific, Qiagen, and Bio-Rad
|
Real Time Polymerase Chain Reaction Market Segment Insights
Cepheid’s SmartCycler segment is projected to represent a key market share
Based on instruments, the Europe real time polymerase chain reaction market is divided into Applied Biosystems/Life Technologies, Roche, Bio Rad, Cepheid, Qiagen, and Eppendorf. The Applied Biosystems/Life Technologies segment is further segmented into 7500, QuantStudio Dx Reagents, ViiA 7 Dx, and StepOne/ StepOne Plus. The Roche segment consists of LightCycler 2.0, Cobas 4800, and LightCycler 480.
The Bio Rad and Cepheid segments include CFX96 and SmartCycler respectively while Qiagen segment includes Rotor-Gene Q and Eppendorf segment includes MasterCycler. The Cepheid’s SmartCycler PCR instrument segment is anticipated to expand at a rapid pace during the forecast period due to high speed and multiplex capabilities of testing.

Germany is anticipated to dominate the market
On the basis of region, the Europe real time polymerase chain reaction market is divided into the UK, Germany, Spain, France, and the Rest of Europe.
Germany is anticipated to dominate the market by representing a high CAGR during the forecast period. The market growth in the country can be attributed to the presence of advanced healthcare facilities combined with high healthcare spending from players, and high knowledge levels among the target audience. However, the combined market of France and Spain are expected to exhibit a rapid growth rate in the coming years due to an increasing economy and rising demand for the testing.
Segments
The Europe real time polymerase chain reaction market has been segmented on the basis of
Instruments
- Applied Biosystems/ Life Technologies
- 7500
- QuantStudio Dx Reagents
- ViiA 7 Dx
- StepOne/ StepOne Plus
- Roche
- LightCycler 2.0
- Cobas 4800
- LightCycler 480
- Bio-Rad
- Cepheid
- Qiagen
- Eppendorf
Region
Key Players
Competitive Landscape
Key players competing in the Europe real time polymerase chain reaction market include Applied Biosystems/Thermo Fischer Scientific, Qiagen, and Bio-Rad. Some of these players are focusing to adopt several business strategies including new product development, mergers, and acquisitions to increase their market shares. For instance, in 2008, Qiagen purchased Corbett Life Sciences, which possessed a number of PCR instruments such as the Rotor-Gene 6000 and Rotor-Gene 3000.
